Introduction
Surgical resection remains the only form of curative treatment in lung cancer but is feasible in only a small percentage of patients.1 A successful outcome depends on accurate staging of the tumour preoperatively and only those patients with a localised tumour or disease with limited spread are usually considered for this form of treatment.2 The present staging procedures are unsatisfactory because they may fail to detect disseminated tumour spread, to judge by the low five year survival rates of patients with resected lung cancer. Mediastinoscopy and computed tomography have improved the accuracy of mediastinal staging considerably in recent years,3 although occult distant spread of tumour may remain undetected by conventional screening tests such as biochemical tests on serum and radionuclide screening.
Immunological abnormaiities have been described in association with several neoplastic disorders. In most instances they are considered to be secondary to the underlying disease process. In particular, there have been reports of altered monocyte function in patients with various solid tumours, including bronchial carcinoma4; for example, monocyte chemotaxis5 and monocyte maturation6 have been shown to be defective in patients with metastatic lung cancer. Reports of animal experiments have indicated that tumours elaborate small molecular weight factors (6000-10 000 daltons) that inhibit monocyte chemotaxis and so prevent potentially tumoricidal macrophages from accumulating at the site of developing tumours.7 Furthermore, similar material obtained from homogenates of human lung cancer was shown to inhibit chemotactic factor induced activation of normal peripheral blood monocytes as assessed by complement receptor enhancement.8 More recently we have shown that peripheral blood monocytes from patients with bronchial carcinoma showed less monocyte complement receptor enhancement than did monocytes from normal individuals and patients with non-malignant respiratory diseases.9
In general, the results of previously described 53 54 immunological assessment, such as monocyte maturation6 and chemotaxis,5 do not distinguish clearly between subjects from control groups and individuals with malignancy. Consequently such tests as these are of limited clinical value. Contrary to our expectations, however, results of monocyte complement receptor enhancement in cells obtained from patients with bronchial carcinoma were clearly different from those obtained from control groups. Furthermore, the degree of depression of monocyte complement receptor enhancement by lung cancer appeared to be related to the extent of the disease.
For these reasons, we have compared monocyte complement receptor enhancement with a number of conventional screening tests to determine whether it might be useful in clinical practice as a means of determining the extent of the disease.
Methods
Forty five patients with lung cancer were studied at the time of diagnosis and before initiation of treatment for their tumours ( findings and the results of one or more of the above investigations. One patient in this group had a thoracotomy. The respiratory controls comprised individuals who had developed serious complications of their conditions. They were matched with patients with bronchial carcinoma for age, smoking history, and depression of serum albumin.
All patients had the following routine haematological and biochemical tests: total and differential white cell counts; erythrocyte sedimentation rate (ESR); and estimations of serum albumin, bilirubin, aspartate transaminase, y glutamyl transpeptidase, and alkaline phosphatase.
The monocyte complement receptor enhancement assay used a rosette technique using sheep red cells (E) sensitised with rabbit IgM (EAM) and incubated with human R3 reagent,9 stabilised with suramin as a source of complement. Enhancement of the complement receptors was performed by preincubation of the monocytes with the chemotactic agent f-met-leuphe.9 Optimal increases in monocyte complement rosettes on monocytes from both patients and controls were usually achieved with 10 -'or 10 -8 mol/l of f-met-leu-phe, but inhibition was generally observed at 10-7mol/l. Percentage changes in monocyte complement rosettes (figs I and 2, table 2) were calculated as follows: monocyte rosettes (%) with FMLP (optimal concentrations)-monocyte rosettes (%) with diluent alone/monocyte rosettes (%) with diluent alone x 100.
Statistical analysis was performed by means of Wilcoxon's rank sum test for non-parametric data.
Results
The slide to slide variations in the numbers of monocyte complement rosettes were calculated. The coefficients of variations of five replicate slides from three separate sets of cells were 8-6%, 11.2%, and 8-1% before enhancement and 11%, 5 7%, and 13-1% after incubation with f-met-leu-phe. The reproducibility of monocyte complement receptor enhancement during the period of the study was assessed on control cells from three individuals, measured on five different occasions, throughout the 20 month study period. showed no monocyte complement receptor enhancement.
The results of monocyte complement receptor enhancement are shown in figures 1 and 2. There were significant differences in monocyte complement receptor enhancement between patients with bronchial carcinoma (total) and healthy controls (p < 0 001), respiratory controls (p < 0.001), older controls (p < 0 001) and smoking controls (p < 0 001) (fig 1) . No significant differences in monocyte complement receptor enhancement were observed between the healthy controls as a whole and older controls or smoking controls, but when healthy controls were compared with respiratory controls the values did just reach significance at p < 0 05. When the patients were divided into groups on the basis of the extent of the disease (fig 2) highly significant differences were observed: metastatic v thoracic and localised (p < 0.001), localised v thoracic (p < 01005). The significance of the differences between all the control groups-healthy, older, smoking, and respiratory-and both the metastatic and the thoracic carcinoma groups-was p < 0-001. By contrast, no significant difference was seen between the localised carcinoma group and any of the control groups. There was no additional association between monocyte complement receptor enhancement and the pathohistological type (that is, squamous, oat cell, adenocarcinoma, and undifferentiated) when the extent of the tumour was taken into account.
The results of routine haematological and biochemical tests, together with the monocyte complement receptor enhancement, are shown in table 2. Although no patient with localised disease had abnormal monocyte complement receptor enhancement, three out of the five patients had at least one abnormality in one of the routine tests. The single test result most frequently outside the normal range was the ESR, which was raised in 20% of the patients.
Patients with thoracic disease were found to have reduced monocyte complement receptor enhancement in 10 out of 12 cases (83%); among the other tests, the ESR was the most frequently abnormal value in five out of 11 cases (45.5%). All 28 patients with metastatic disease had a monocyte complement receptor enhancement value less than 30%. This was the lowest value obtained from the group of 48 healthy controls, including the seven older healthy controls and nine smoking controls, and 12 respiratory controls (figs I and 2). Although 67% of these patients with metastatic disease also had a raised ESR, and the alkaline phosphatase and y glutamyl transpeptidase activities and albumin concentration were abnormal in 64%, 59%, and 50% respectively, the remaining patients had values within the normal range. When all the routine tests were taken together, however, an abnormality in at least one of the results was seen in 25 of the 28 patients.
Discussion
We have shown that a test of monocyte function, monocyte complement receptor enhancement, showed reduced values on cells from patients with bronchial carcinoma and that this was related to the stage of the disease. We have previously shown that baseline monocyte complement rosettes (that is, without enhancement) were no different when monocytes from patients with bronchial carcinoma were compared with those from controls.9 Thus monocyte complement receptor enhancement appears to give further information on monocyte function and might have useful diagnostic implications. Patients with localised disease had monocyte complement receptor enhancement within a normal range previously established for healthy individuals (fig 1) . There were, however, only five patients in this group and so we cannot exclude the possibility that if a larger number had been studied, even those patients with localised disease might have had abnormal values, particularly if an individual had a large but nevertheless localised tumour. In patients whose disease had spread, either within the chest or to produce widespread metastases, monocyte complement receptor enhancement was 56 
